Abstract
Introduction
Breast cancer remains the most common cancer in females. It has been estimated that one in eight women will develop breast cancer during their lifetime in the USA [1] Approximately two thirds of postmenopausal breast cancer patients have hormone dependent breast cancer that requires estrogen for tumour growth. It is well established that estrogens enhance growth and proliferation of certain target cells such as breast epithelial cells and estrogen dependent mammary carcinoma cells [2] .
In postmenopausal women, estradiol does not appear to function as a circulating hormone; it is biosynthesized from androgens by the cytochrome P450 enzyme complex called aromatase [3] which is a product of the CYP19 gene, with the highest levels of this enzyme present in the peripheral adipose tissues of postmenopausal women [3] . Estrogen acts mainly at a local level as a paracrine or intracrine factor.
Aromatase has been found and measured in the stromal cell component of the normal breast as well as the breast tumour. Also, the enzyme has been detected in the breast epithelial cells in vitro [4] [5] [6] [7] [8] . Furthermore, expression of aromatase is highest in or near breast tumour sites [5, 6, 9, 10] . It has been observed that the aromatase activity and expression is highest in the breast quadrant containing the tumour, such expression in the tumour containing quadrant is equal to that in the tumour itself, but double that in a quadrant of the same breast which does not contain a tumour which in turn is double the expression in the cancer free breast [10] .
Evidence that postmenopausal obesity and weight gain are positively associated with postmenopausal breast cancer risk has been substantiated especially in women who never used hormone replacement therapy [11] .
The aim of this study was to examine the hypothesis questioning the relationship between oestrogen and progesterone receptor status and breast tissue weight in postmenopausal women who had mastectomy for operable breast cancer.
Patients and methods
The mastectomy specimen weight, estrogen receptor (ER) and progesterone receptor (PgR) status for 62 consecutive patients who had a total mastectomy for operable breast cancer were retrospectively reviewed. Breast specimen weight was obtained from the pathology laboratory reports in grams. ER and PgR status was determined by immunohistochemistry (IHC) using the Quickscore system by a breast pathologist. ER/PgR status was considered positive if the score was 4 -8. We also examined other parameters including tumour size, grade, nodal status, cerb B2 expression and patient's age.
Correlation between breast weight and receptor status was examined in two groups of patients according to their age, 50 years and older and younger than 50 years.
Results
59 patients had invasive breast cancer and 3 patients had ductal carcinoma in situ (DCIS). Estrogen receptors were positive (ER+) in 50 patients (Quickscore: 4-8) and negative (ER-) in 12 patients (Quickscore: 0)
In general, breast weight was higher in patients with ER+ disease; median weight was 570 grams in ER+ patients compared to 413 grams in ER-patients (p = 0.04) Patients were divided into two groups according to age. The first group consisted of patient aged 50 years and over (n = 43) with a median age of 60 years (range 51-83) and the second group contained those patients aged less than 50 years (n = 19) with a median age of 42 years (range 29-48).
Within the first group, breast weight was found to be significantly higher in women with ER+ tumours (669 vs. 220 grams, p = 0.015). Figure (1) demonstrates the relationship between the mastectomy specimen weight and ER status in the first group. Furthermore, when ER-and PgR -tumours were considered together the association was stronger (p = 0.003). On the other hand, there was no significant difference in breast weight between ER+ and ER-tumours in women in the second group (median weight: 440 vs.408 grams, p = 0.379).
There was no significant difference in tumour's size between ER+ and ER-patients. Furthermore, the tumour's grade was higher in ER-patients (p = 0.009) and patient's age had no significant impact on the receptor status.
We observed a non-significant association between higher breast weight and PgR positivity (809 vs. 510 grams, p = 0.084) and absence of c-erb B2 (p = 0.088).
Finally, there was no association between breast weight and nodal status or tumour's grade.
Discussion
It has been established that obesity and weight gain are risk factors of breast cancer in postmenopausal women [12] . This relationship is explained by the fact that increased body weight is due to increased amount of adipose tissue in the body including breasts and subsequently increased of aromatase activity, thus increasing the local production of estrogen by aromatization of circulating androgens [13] [14] [15] [16] . This process is a very ER status and mastectomy weight important growth stimulating system in hormone dependent breast cancer [17] .
Breast tissue and particularly the breast adipose tissue in postmenopausal women with breast cancer seem to have an increased aromatase expression. Agrawel et al studied 9 women undergoing breast reduction mammoplasty and 18 breast cancer patients undergoing mastectomies. Nontumour bearing adipose samples from mastectomies expressed significantly more aromatase than adipose tissue taken from mammoplasty patients, a difference that is unlikely to be due the tumour's influence on aromatase expression [10] .
The relationship between a higher body mass index (BMI) and the risk of ER+/PgR+ breast cancer has been studied previously [18] [19] [20] [21] [22] [23] . In a case control study by Shelley et al a significantly increased risk of ER+/PgR+ breast cancer with increasing body size was observed. On contrast, other studies showed a greater frequency of ER-breast cancer among obese women [24] [25] [26] [27] .
The relationship between increased breast weight in postmenopausal women and receptor status has not been previously examined. In our study we hypothesised that in breast cancer patients; ER+ breast cancer was associated with a higher breast weight than ER-disease. This hypothesis was proved to be correct in postmenopausal women. Furthermore, such an association was not observed in women aged less than 50 years.
Our study has several limitations; firstly, we did not include other risk factors such as body mass index. Although a higher BMI is a recognised risk factor for ER+ disease, larger breasts are not always associated with a high BMI; higher breast weight could be found in a normal or low BMI postmenopausal women.
Secondly the family and HRT histories were not included in the analysis. Thirdly, the weight of the formatin-fixed mastectomy specimen was measured rather than the weight of the fresh specimen. However this applies to all specimens and is therefore unlikely to alter our findings. Finally we used the age of 50 years rather than the date of the last menstrual period to define the menopausal status. These limitations could be tackled in a larger prospective study.
In summary, in women aged 50 years or older with breast cancer, a higher breast weight seems to be significantly associated with ER+ disease. If this is confirmed in larger prospective studies, our findings may have implications regarding breast cancer prevention with anti-estrogens.
